Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732524 · ClinicalTrials.gov registry record · Phase 4
Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA
A Phase 4 study, sponsored by Cook County Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT00732524 is a Phase 4 study that has completed, run by Cook County Health. The registered enrollment target is 80 participants.
The verdict
NCT00732524, a Phase 4 study, has completed, sponsored by Cook County Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two simple and safe emergency department discharge therapy for Type 2 Diabetes patients with severe hyperglycemia and with no indications for inpatient admission.
Interventions
- DRUG Glipizide
- DRUG Glipizide and Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732524
The ClinicalTrials.gov registry entry for NCT00732524 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook County Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glipizide is the first listed.
NCT00732524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732524 about?
NCT00732524 is a clinical study titled "Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA". The purpose of this study is to compare two simple and safe emergency department discharge therapy for Type 2 Diabetes patients with severe hyperglycemia and with no indications for inpatient admission.
What is the current status of trial NCT00732524?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2004-09. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00732524?
The interventions under investigation include: Glipizide (DRUG), Glipizide and Glargine (DRUG).
Who is sponsoring clinical trial NCT00732524?
This trial is sponsored by Cook County Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.